Cardiac cell therapy: Lessons from clinical trials

Journal of Molecular and Cellular Cardiology

Volumn 50, Issue 2, 2011, Pages 258-265

  Menasche, Philippe ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Clinical trials; Heart failure; Myocardial infarction; Stem cells

Indexed keywords

ACUTE HEART INFARCTION; ANGINA PECTORIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CELL HOMING; CELL SEPARATION; CELL SURVIVAL; CELL THERAPY; CELL TRANSFER; CORONARY ARTERY BYPASS GRAFT; ENGRAFTMENT; HEART FAILURE; HEART MUSCLE CELL; HEART VENTRICLE ARRHYTHMIA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MESENCHYMAL STEM CELL TRANSPLANTATION; MONONUCLEAR CELL; MYOBLAST; NONHUMAN; OUTCOME ASSESSMENT; PARACRINE SIGNALING; PATIENT SAFETY; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; STANDARDIZATION; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION; TREATMENT INDICATION;

CLINICAL TRIALS AS TOPIC; HEART DISEASES; HUMANS; MYOBLASTS, CARDIAC; STEM CELL TRANSPLANTATION; TISSUE THERAPY;

ANGINA;

EID: 79151475088     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2010.06.010     Document Type: Review

References (71)

1. Martin-Rendon E., Brunskill S.J., Hyde C.J., Stanworth S.J., Mathur A., Watt S.M. Autologous bone marrow stem cells to treat acute myocardial infarction: a systematic review. Eur Heart J 2008, 29:1807-1818.
2. Udelson J.E., Konstam M.A. Relation between left ventricular remodeling and clinical outcomes in heart failure patients with left ventricular systolic dysfunction. J Card Fail 2002, 8(suppl):S-465-S-470.
3. Schächinger V., Erbs S., Elsässer A., Haberbosch W., Hambrecht R., Hölschermann H., et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 2006, 355:1210-1221.
4. Assmus B., Rolf A., Erbs S., Elsässer A., Haberbosch W., Hambrecht R., et al. REPAIR-AMI Investigators. Clinical outcome 2years after intracoronary administration of bone marrow-derived progenitor cells in acute myocardial infarction. Circ Heart Fail 2010, 3:89-96.
5. van der Laan A., Hirsch A., Nijveldt R., van der Vleuten P.A., van der Giessen W.J., Doevendans P.A., et al. Bone marrow cell therapy after acute myocardial infarction: the HEBE trial in perspective, first results. Neth Heart J 2008, 16:436-439.
6. Tendera M., Wojakowski W., Ruzyłło W., Chojnowska L., Kepka C., Tracz W., et al. REGENT Investigators. Intracoronary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: Results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) Trial. Eur Heart J 2009, 30:1313-1321.
7. Huikuri H.V., Kervinen K., Niemelä M., Ylitalo K., Säily M., Koistinen P., et al. Effects of intracoronary injection of mononuclear bone marrow cells on left ventricular function, arrhythmia risk profile, and restenosis after thrombolytic therapy of acute myocardial infarction. Eur Heart J 2008, 29:2723-2732.
8. Wöhrle J., Merkle N., Mailänder V., Nusser T., Schauwecker P., von Scheidt F., et al. Results of intracoronary stem cell therapy after acute myocardial infarction. Am J Cardiol 2010, 105:804-812.
9. Hare J.M., Traverse J.H., Henry T.D., Dib N., Strumpf R.K., Schulman S.P., et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol 2009, 54:2277-2286.
10. Lee R.H., Pulin A.A., Seo M.J., Kota D.J., Ylostalo J., Larson B.L., et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 2009, 5:54-63.
11. Abdel-Latif A., Bolli R., Zuba-Surma E.K., Tleyjeh I.M., Hornung C.A., Dawn B. Granulocyte colony-stimulating factor therapy for cardiac repair after acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials. Am Heart J 2008, 156:216-226.
12. Losordo D.W., Schatz R.A., White C.J., Udelson J.E., Veereshwarayya V., Durgin M., et al. Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial. Circulation 2007, 115:3165-3172.
13. van Ramshorst J., Bax, Jeroen J., Dibbets-Schneider P., Roes S.D., Stokkel M.P., et al. Intramyocardial bone marrow cell injection for chronic myocardial ischemia: a randomized controlled trial. JAMA 2009, 301:1997-2004.
14. Menasché Ph., Alfieri O., Janssens S., McKenna W., Reichenspurner H., Trinquart L., et al. The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) Trial. First randomized placebo-controlled study of myoblast transplantation. Circulation 2008, 117:1189-1200.
15. Dib N., Dinsmore J., Lababidi Z., White B., Moravec S., Campbell A. One-year follow-up of feasibility and safety of the first U.S., randomized, controlled study using 3-dimensional guided catheter-based delivery of autologous skeletal myoblasts for ischemic cardiomyopathy (CAuSMIC study). JACC Cardiovasc Interv 2009, 2:9-16.
16. Veltman C.E., Soliman O.I., Geleijnse M.L., Vletter W.B., Smits P.C., ten Cate F.J., et al. Four-year follow-up of treatment with intramyocardial skeletal myoblasts injection in patients with ischaemic cardiomyopathy. Eur Heart J 2008, 29:1386-1396.
17. Menasche P. Cell-based therapy for heart disease: a clinically oriented perspective. Mol Ther 2009, 17:758-766.
18. Strauer B.E., Brehm M., Zeus T., Bartsch T., Schannwell C., Antke C., et al. Regeneration of human infarcted heart muscle by intracoronary autologous bone marrow cell transplantation in chronic coronary artery disease: the IACT Study. J Am Coll Cardiol 2005, 46:1651-1658.
19. Fischer-Rasokat U., Assmus B., Seeger F.H., Honold J., Leistner D., Fichtlscherer S., et al. A pilot trial to assess potential effects of slective intra-coronary bone marrow-derived progenitor cell infusion in patients with nonischemic dilated cardiomyopathy: final 1-year results of the TOPCARE-DCM trial. Circ Heart Fail 2009, 2:417-423.
20. Stamm C., Kleine H.D., Choi Y.H., Dunkelmann S., Lauffs J.A., Lorenzen B., et al. Intramyocardial delivery of CD133+ bone marrow cells and coronary artery bypass grafting for chronic ischemic heart disease: safety and efficacy studies. J Thorac Cardiovasc Surg 2007, 133:717-725.
21. Seeger F.H., Tonn T., Krzossok N., Zeiher A.M., Dimmeler S. Cell isolation procedures matter: a comparison of different isolation protocols of bone marrow mononuclear cells used for cell therapy in patients with acute myocardial infarction. Eur Heart J 2007, 28:766-772.
22. Assmus B., Tonn T., Seeger F.H., Yoon C.H., Leistner D., Klotsche J., et al. Red blood cell contamination of the final cell product impairs the efficacy of autologous bone marrow mononuclear cell therapy. J Am Coll Cardiol 2010, 55:1385-1394.
23. Prokopi M., Pula G., Mayr U., Devue C., Gallagher J., Xiao Q., et al. Proteomic analysis reveals presence of platelet microparticles in endothelial progenitor cell cultures. Blood 2009, 114:723-732.
24. Zhao Q., Sun Y., Xia L., Chen A., Wang Z. Randomized study of mononuclear bone marrow cell transplantation in patients with coronary surgery. Ann Thorac Surg 2008, 86:1833-1840.
25. Akar A.R., Durdu S., Arat M., Kilickap M., Kucuk N.O., Arslan O., et al. Five-year follow-up after transepicardial implantation of autologous bone marrow mononuclear cells to ungraftable coronary territories for patients with ischaemic cardiomyopathy. Eur J Cardiothorac Surg 2009, 36:633-643.
26. Schächinger V., Aicher A., Döbert N., Röver R., Diener J., Fichtlscherer S., et al. Pilot trial on determinants of progenitor cell recruitment to the infarcted human myocardium. Circulation 2008, 118:1425-1432.
27. Freyman T., Polin G., Osman H., Crary J., Lu M., Cheng L., et al. A quantitative, randomized study evaluating three methods of mesenchymal stem cell delivery following myocardial infarction. Eur Heart J 2006, 27:1114-1122.
28. Brunskill S.J., Hyde C.J., Doree C.J., Watt S.M., Martin-Rendon E. Route of delivery and baseline left ventricular ejection fraction, key factors of bone-marrow-derived cell therapy for ischaemic heart disease. Eur J Heart Fail 2009, 11:887-896.
29. Abraham M.R., Henrikson C.A., Tung L., Chang M.G., Aon M., Xue T., et al. Antiarrhythmic engineering of skeletal myoblasts for cardiac transplantation. Circ Res 2005, 97:159-167.
30. Fukushima S., Varela-Carver A., Coppen S.R., Yamahara K., Felkin L.E., Lee J., et al. Direct intramyocardial but not intracoronary injection of bone marrow cells induces ventricular arrhythmias in a rat chronic ischemic heart failure model. Circulation 2007, 115:2254-2261.
31. Soliman A.M., Krucoff M.W., Crater S., Morimoto Y., Taylor D.A. Cell location may be a primary determinant of safety after myoblast transplantation into the infarcted heart. J Am Coll Cardiol 2004, 43:15A. [abstract].
32. Chen H.S., Kim C., Mercola M. Electrophysiological challenges of cell-based myocardial repair. Circulation 2009, 120:2496-2508.
33. Amariglio N., Hirshberg A., Scheithauer B.W., Cohen Y., Loewenthal R., Trakhtenbrot L., et al. Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med 2009, 6:e1000029.
34. Uemura R., Xu M., Ahmad N., Ashraf M. Bone marrow stem cells prevent left ventricular remodeling of ischemic heart through paracrine signaling. Circ Res 2006, 98:1414-1421.
35. Dai Y., Ashraf M., Zuo S., Uemura R., Dai Y.S., Wang Y., et al. Mobilized bone marrow progenitor cells serve as donors of cytoprotective genes for cardiac repair. J Mol Cell Cardiol 2008, 44:607-617.
36. Kinnaird T., Stabile E., Burnett M.S., Lee C.W., Barr S., Fuchs S., et al. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res 2004, 94:678-685.
37. Cho H.J., Lee N., Lee J.Y., Choi Y.J., Ii M., Wecker A., et al. Role of host tissues for sustained humoral effects after endothelial progenitor cell transplantation into the ischemic heart. J Exp Med 2007, 204:3257-3269.
38. Timmers L., Lim S.K., Arslan F., Armstrong J.S., Hoefer I.E., Doevendans P.A., et al. Reduction of myocardial infarct size by human mesenchymal stem cell conditioned medium. Stem Cell Res 2007, 1:129-137.
39. Lai R.C., Arslan F., Lee M.M., Sze N.S., Choo A., Chen T.S., et al. Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Res 2010, 4:314-322.
40. Rehman J., Traktuev D., Li J., Merfeld-Clauss S., Temm-Grove C.J., Bovenkerk J.E., et al. Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Circulation 2004, 109:1292-1298.
41. Miettinen J.A., Ylitalo K., Hedberg P., Jokelainen J., Kervinen K., Niemelä M., et al. Determinants of functional recovery after myocardial infarction of patients treated with bone marrow-derived stem cells after thrombolytic therapy. Heart 2010, 96:362-367.
42. Schaefer A., Zwadlo C., Fuchs M., Meyer G.P., Lippolt P., Wollert K.C., et al. Long-term effects of intracoronary bone marrow cell transfer on diastolic function in patients after acute myocardial infarction: 5-year results from the randomized-controlled BOOST trial-an echocardiographic study. Eur J Echocardiogr 2010, 11:165-171.
43. Valina C., Pinkernell K., Song Y.H., Bai X., Sadat S., Campeau R.J., et al. Intracoronary administration of autologous adipose tissue-derived stem cells improves left ventricular function, perfusion, and remodelling after acute myocardial infarction. Eur Heart J 2007, 28:2667-2677.
44. Caplan A.I., Dennis J.E. Mesenchymal stem cells as trophic mediators. J Cell Biochem 2006, 98:1076-1084.
45. Bartunek J., Croissant J.D., Wijns W., Gofflot S., de Lavareille A., Vanderheyden M., et al. Pretreatment of adult bone marrow mesenchymal stem cells with cardiomyogenic growth factors and repair of the chronically infarcted myocardium. Am J Physiol Heart Circ Physiol 2007, 292:H1095-H1104.
46. Bearzi C., Rota M., Hosoda T., Tillmanns J., Nascimbene A., De Angelis A., et al. Human cardiac stem cells. Proc Natl Acad Sci USA 2007, 104:14068-14073.
47. Pouly J., Bruneval P., Mandet C., Proksch S., Peyrard S., Amrein C., et al. Cardiac stem cells in the real world. J Thorac Cardiovasc Surg 2008, 135:673-678.
48. Blin G., Nury D., Stefanovic S., Neri T., Guillevic O., Brinon B., et al. A purified population of multipotent cardiovascular progenitors derived from primate pluripotent stem cells engrafts in postmyocardial infarcted nonhuman primates. J Clin Invest 2010, 120:1125-1139.
49. Nelson T.J., Martinez-Fernandez A., Yamada S., Perez-Terzic C., Ikeda Y., Terzic A. Repair of acute myocardial infarction with induced pluripotent stem cells Induced by human stemness factors. Circulation 2009, 120:408-416.
50. Li T.S., Kubo M., Ueda K., Murakami M., Mikamo A., Hamano K. Impaired angiogeneic potency of bone marrow cells from patients with advanced age, anemia and renal failure. J Thorac Cardiovasc Surg 2010, 139:459-465.
51. Kissel C.K., Lehmann R., Assmus B., Aicher A., Honold J., Fischer-Rasokat U., et al. Selective functional exhaustion of hematopoietic progenitor cells in the bone marrow of patients with postinfarction heart failure. J Am Coll Cardiol 2007, 49:2341-2349.
52. Sorrentino S.A., Bahlmann F.H., Besler C., Muller M., Schulz S., Kirchhoff N., et al. Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: Restoration by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation 2007, 116:163-173.
53. Assmus B., Fischer-Rasokat U., Honold J., Seeger F.H., Fichtlscherer S., Tonn T., et al. TOPCARE-CHD Registry. Transcoronary transplantation of functionally competent BMCs is associated with a decrease in natriuretic peptide serum levels and improved survival of patients with chronic postinfarction heart failure: Results of the TOPCARE-CHD Registry. Circ Res 2007, 100:1234-1241.
54. Ryan J.M., Barry F.P., Murphy J.M., Mahon B.P. Mesenchymal stem cells avoid allogeneic rejection. J Inflamm (Lond) 2005, 2:8.
55. Uccelli A., Pistoia V., Moretta L. Mesenchymal stem cells: a new strategy for immunosuppression?. Trends Immunol 2007, 28:219-226.
56. Poncelet A.J., Vercruysse J., Saliez A., Gianello P. Although pig allogeneic mesenchymal stem cells are not immunogenic in vitro, intracardiac injection elicits an immune response in vivo. Transplantation 2007, 83:783-790.
57. Cheng K., Li T.S., Malliaras K., Davis D., Zhang Y., Marbán E. Magnetic targeting enhances engraftment and functional benefit of iron-labeled cardiosphere-derived cells in myocardial infarction. Circ Res 2010, April8. Electronic Publication.
58. Hofmann M., Wollert K.C., Meyer G.P., Menke A., Arseniev L., Hertenstein B., et al. Monitoring of bone marrow cell homing into the infarcted human myocardium. Circulation 2005, 111:2198-2202.
59. Wang X., Jameel M.N., Li Q., Mansoor A., Qiang X., Swingen C., et al. Stem cells for myocardial repair with use of a transarterial catheter. Circulation 2009, 120(11 Suppl):S238-S246.
60. Ghanem A., Steingen C., Brenig F., Funcke F., Bai Z.Y., Hall C., et al. Focused ultrasound-induced stimulation of microbubbles augments site-targeted engraftment of mesenchymal stem cells after acute myocardial infarction. J Mol Cell Cardiol 2009, 47:411-418.
61. Cheng Z., Ou L., Zhou X., Li F., Jia X., Zhang Y., et al. Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance. Mol Ther 2008, 16:571-579.
62. Elmadbouh I., Haider H.Kh., Jiang S., Idris N.M., Lu G., Ashraf M. Ex vivo delivered stromal cell-derived factor-1alpha promotes stem cell homing and induces angiomyogenesis in the infarcted myocardium. J Mol Cell Cardiol 2007, 42:792-803.
63. Zhang M., Methot D., Poppa V., Fujio Y., Walsh K., Murry C.E. Cardiomyocyte grafting for cardiac repair: graft cell death and anti-death strategies. J Mol Cell Cardiol 2001, 33:907-921.
64. Niagara M.I., Haider H.Kh., Jiang S., Ashraf M. Pharmacologically preconditioned skeletal myoblasts are resistant to oxidative stress and promote angiomyogenesis via release of paracrine factors in the infarcted heart. Circ Res 2007, 100:545-555.
65. Winter E.M., van Oorschot A.A.M., Hogers B., van der Graaf L.M., Doevendans P.A., Poelmann R.E., et al. A new direction for cardiac regeneration: application of synergistically acting epicardium-derived cells and cardiomyocyte progenitor cells. Circ Heart Fail 2009, 2:643-653.
66. Zhang G., Hu Q., Braunlin E.A., Suggs L.J., Zhang J. Enhancing efficacy of stem cell transplantation to the heart with a PEGylated fibrin biomatrix. Tissue Eng A 2008, 14:1025-1036.
67. Padin-Iruegas M.E., Misao Y., Davis M.E., Segers V.F., Esposito G., Tokunou T., et al. Cardiac progenitor cells and biotinylated insulin-like growth factor-1 nanofibers improve endogenous and exogenous myocardial regeneration after infarction. Circulation 2009, 120:876-887.
68. Zimmermann W.H., Melnychenko I., Wasmeier G., Didié M., Naito H., Nixdorff U., et al. Engineered heart tissue grafts improve systolic and diastolic function in infarcted rat hearts. Nat Med 2006, 12:452-458.
69. Hamdi H., Furuta A., Bellamy V., Bel A., Puymirat E., Peyrard S., et al. Cell delivery: intramyocardial injections or epicardial deposition? A head-to-head comparison. Ann Thorac Surg 2009, 87:1196-1203.
70. Stevens K.R., Kreutziger K.L., Dupras S.K., Korte F.S., Regnier M., Muskheli V., et al. Physiological function and transplantation of scaffold-free and vascularized human cardiac muscle tissue. Proc Natl Acad Sci USA 2009, 106:16568-16573.
71. Herbots L., D'hooge J., Eroglu E., Thijs D., Ganame J., Claus P., et al. Improved regional function after autologous bone marrow-derived stem cell transfer in patients with acute myocardial infarction: a randomized, double-blind strain rate imaging study. Eur Heart J 2009, 30:662-670.